Tag Archives: Rinvoq

Abbvie’s Rinvoq matches BMS’ Orencia in head-to-head rheumatoid arthritis trial

With megablockbuster Humira on the decline, AbbVie is hoping for big things from its next-gen JAK inhibitor Rinvoq. Now, in a head-to-head rheumatoid arthritis battle with Bristol Myers Squibb’s blockbuster Orencia, Rinvoq has come out on top. Rinvoq matched Bristol’s Orencia in easing rheumatoid arthritis patients’ symptoms at the 12-week mark and bested its older rival in patient remission rates, according to… Read More »

FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis

FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis Print this page NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral… Read More »